Adverse drug events in out-patients as the cause of an initial consultation to neurology;Acontecimientos adversos por medicamentos en pacientes ambulatorios como motivo de primera consulta a neurología

Neurologia

Volumn 21, Issue 5, 2006, Pages 232-238

  Ortín Castaño, Antonio ^a,b   Otero, M J ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b NONE   (Spain)

Author keywords

Adverse drug events; Latrogenic disease; Medication errors; Medication overuse headache; Neurology consultation; Trimetazidine

Indexed keywords

ACETYLSALICYLIC ACID; BIPERIDEN; CLEBOPRIDE; CODEINE; DEXKETOPROFEN; DIHYDROERGOTAMINE; DIPYRONE; ERGOT DERIVATIVE; ERGOTAMINE; FENTANYL; HALOPERIDOL; IBUPROFEN; KETOROLAC; LEVOMEPROMAZINE; MORPHINE; MOXIFLOXACIN; OLANZAPINE; PARACETAMOL; PAROXETINE; QUETIAPINE; RISPERIDONE; SERTRALINE; SULPIRIDE; TRIMETAZIDINE; VENLAFAXINE; ZOLMITRIPTAN;

ADULT; ARTICLE; CONFUSION; CONSULTATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ABUSE; DRUG OVERDOSE; DYSKINESIA; FEMALE; HEADACHE; HEALTH EDUCATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICATION ERROR; NEUROLOGIC DISEASE; NEUROLOGY; OUTPATIENT CARE; PARKINSONISM; PRESCRIPTION; PUBLIC HEALTH; SELF MEDICATION; TREATMENT DURATION; TREMOR;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MEDICATION ERRORS; MIDDLE AGED; NEUROLOGY; OUTPATIENTS; PHARMACEUTICAL PREPARATIONS; PROSPECTIVE STUDIES; REFERRAL AND CONSULTATION;

EID: 33745966671     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. La industria farmacéutica en cifras. Edición 2004. Farmaindustria (consultado 22-08-05). Disponible en: www.farmaindustria.es.
2. Rodriguez-Monguió R, Otero MJ, Rovira J. Assessing the economic impact of adverse drug effects. Pharmacoeconomics 2003;21:623-50.
3. Alonso Hernéndez P, Otero López MJ, Maderuelo Fernández JA. Ingresos hospitalarios causados por medicamentos: incidencia, características y coste. Farmacia Hosp 2002;26:77-89.
4. Winterstein AG, Sauer BC, Hepler CD, Poole C. Preventable drug-related hospital admissions. Ann Pharmacother 2002;36:1238-48.
5. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as a cause of admissions to hospital: prospective analysis of 18,820 patients. BMJ 2004;329:15-9.
6. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential drug events. Implications for prevention. JAMA 1995;274:29-34.
7. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA 1998;279:1200-5.
8. Otero MJ, Alonso Hernández P, Maderuelo Fernández JA, Garrido Corro B, Domínguez-Gil A, Sánchez Rodríguez A. Acontemientos adverses prevenibles por medicamentos en pacientes hospitalizados. Med Clin (Barc) 2006;126:81-7.
9. Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, et al. Adverse drug events in ambulatory care. N Engl J Med 2003;348:1556-64.
10. Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003;289:1107-16.
11. Dormann H, Criegee-Rieck M, Neubert A, Egger T, Geise A, Krebs S, et al. Lack of awareness of community-acquired adverse drug reactions upon hospital admission. Dimensions and consequences of a dilemma. Drug Saf 2003;26:353-62.
12. Rochon PA, Gurwitz JH. Optimizing drug treatment for elderly people: the prescribing cascade. BMJ 1997;315:1096-9.
13. Glick TH. The neurologist and patient safety. Neurologist 2005;11:140-9.
14. Moses H, Kaden I. Neurologic consultations in a general hospital: spectrum of iatrogenic disease. Am J Med 1986;81:955-8.
15. Morrow JI, Patterson VH. The neurological practice of a general hospital. J Neurol Neurosurg Psychiat 1987;50:1397-401.
16. Thuermann PA, Windecker R, Steffen J, Schaefer M, Tenter U, Reese E, et al. Detection of adverse drug reactions in a neurological department. Comparison between intensified surveillance and a computer-assisted approach. Drug Saf 2002;25:713-24.
17. Morimoto T, Gandhi TK, Seger AC, Hsieh TC, Bates DW. Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care 2004;13:306-14.
18. Centros Autónomes de Farmacovigilancia. Manual de Codificación Madrid: Ministerio de Sanidad y Consumo, 1994.
19. Schumock GT, Thornton JP. Focusing on preventability of adverse drug reactions. Hosp Pharm 1992;27:538.
20. Otero López MJ, Codina Jané C, Tamés Alonso MJ, Pérez Encinas M, en representación del Grupo de Trabajo Ruiz-Jarabo 2000. Errores de medicación: estandarización de la terminología y clasificación. Farmacia Hosp 2003;27:137-49.
21. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004;24(Suppl. 1):1-160.
22. Colás R, Muñoz P, Temprano R, Gómez C, Pascual J. Chronic daily headache with analgesic overuse. Epidemiology and impact on quality of life. Neurology 2004;62:1338-42.
23. Pascual J, Berciano J. Cefalea crónica diaria de pacientes migrañosos inducida por abuso de analgésicos-ergotamínicos: respuesta a un protocolo de tratamiento ambulatorio. Neurología 1993;8:212-5.
24. Smith TR, Stoneman J. Medication overuse headache from anti-migraine therapy. Clinical features, pathogenesis and management. Drugs 2004;64:2503-14.
25. Bekkelund SI, Salvesen R. Drug-associated headache is unrecognized in patients treated at a neurological centre. Acta Neurol Scand 2002;105:120-3.
26. Limmroth V, Katsarava Z. Medication overuse headache. Curr Opin Neurol 2004;17:301-6.
27. Guitera V, Muñoz P, Castillo J, Pascual J. Quality of life in chronic daily headache. A study in a general population. Neurology 2002;58:1062-5.
28. Morgante L, Rocca WA, De Rosa AE, De Domenico P, Grigoletto F, Meneghini F, et al. Prevalence of Parkinson's disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities. The Sicilian Neuro-Epidemiology Study (SNES) Group. Neurology 1992;42:1901-7.
29. Trenkwalder C, Schwarz J, Gebhard J, Ruland D, Trenkwalder P, Hense H-W, et al. Starnberg trial on epidemiology of parkinsonism and hypertension in the elderly: prevalence of Parkinson's disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch Neurol 1995;52:1017-22.
30. Martí Massó JF, Poza JJ. Parkinsonismo inducido o agravado por fármacos: características clínicas y evolución histórica de los fármacos implicados. Neurología 1996;11:10-5.
31. Martí-Massó JF, Carrera N, Urtasun M. Drug-induced parkinsonism: a growing list. Mov Dis 1993;8:125.
32. Jiménez-Jiménez FJ, Garcia-Ruiz PJ, Molina JA. Drug-induced movements disorders. Drug Safety 1997;16:180-204.
33. Martí Massó JF. Parkinsonismo por trimetazidina. Neurología 2004;19:392-5.
34. Sommet A, Azaïs-Vuillemin C, Bagheri H, Rascol O, Montastruc JL. Trimetazidine: a new cause for drug-induced parkinsonism? Mov Disord 2005;20:1080-1.
35. Jiménez-Jiménez FJ, Tejeiro J, Martínez-Junquera G, Cabrera-Valdivia F, Alarcón J, García-Albea E. Parkinsonism exacerbated by paroxetine. Neurology 1994;44:2406.
36. Cano A, Roquer J. Parkinsonismo secundario al uso de sertralina. Med Clin (Barc) 1995;105:797-8.
37. Pina Latorre MA, Zabala López S. Parkinsonismo reversible secundario a la toma de sertralina. Neurología 1998;13:444-5.
38. Garcia-Parajuá P, Álvarez Iniesta I, Magariños M. Parkinsonismo reversible y dependiente de la dosis inducido por venlafaxina. Med Clin (Barc) 2003;120:756-9.
39. Avery AJ, Sheikh A, Hurwitz B, Smeaton L, Chen Y-F, Howard R, et al. Safer medicines management in primary care. Br J Gen Pract 2002;52(Suppl.):S17- 22.
40. Task Force on Medicines Partnership. Room for review: a guide to medication review. London: Medicines Partnership, 2002.